ArticleWorld journal of gastroenterology2006
Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer.
Article in World journal of gastroenterology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 39 citations in OpenAlex.
- Alteration of ribosome function upon 5-fluorouracil treatment favors cancer cell drug-tolerance.Nature communications · 2022Article
- Relation of the IGF/IGF1R system to autophagy in colitis and colorectal cancer.World journal of gastroenterology · 2017Review
- Type I insulin-like growth factor receptor signaling in hematological malignancies.Oncotarget · 2017Review
- Curcumol Inhibits Growth and Induces Apoptosis of Colorectal Cancer LoVo Cell Line via IGF-1R and p38 MAPK Pathway.International journal of molecular sciences · 2015Article
- Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Article
- The roles of PIKE in tumorigenesis.Acta pharmacologica Sinica · 2013Review
- Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?Therapeutic advances in medical oncology · 2013Article
- Dual targeting of the insulin-like growth factor and collateral pathways in cancer: combating drug resistance.Cancers · 2011Article
- The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models.Clinical cancer research : an official journal of the American Association for Cancer Research · 2010Article
- Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance.World journal of gastroenterology · 2010Article
- IGF-IR and its inhibitors in gastrointestinal carcinomas (Review).Oncology letters · 2010Article
- Targeted medical therapy of biliary tract cancer: recent advances and future perspectives.World journal of gastroenterology · 2008Review
- Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials.Molecular cancer therapeutics · 2008Review
- Role of insulin-like growth factor-1R system in colorectal carcinogenesis.Critical reviews in oncology/hematology · 2008Review
- Liver regeneration and tumor stimulation--a review of cytokine and angiogenic factors.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2008Review
- Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives.World journal of gastroenterology · 2008Review
- Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer.World journal of gastroenterology · 2008Review
- Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells.World journal of gastroenterology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the antineoplastic potency of the novel insulin-like growth factor 1 receptor (IGF-1R) tyrosine kinase inhibitor (TKI) NVP-AEW541 in cell lines and primary cell cultures of human colorectal cancer (CRC).
methodsCells of primary colorectal carcinomas were from 8 patients. Immunostaining and crystal violet staining were used for analysis of growth factor receptor protein expression and detection of cell number changes, respectively. Cytotoxicity was determined by measuring the release of the cytoplasmic enzyme lactate dehydrogenase (LDH). The proportion of apoptotic cells was determined by quantifying the percentage of sub-G1 (hypodiploid) cells. Cell cycle status reflected by the DNA content of the nuclei was detected by flow cytometry.
resultsNVP-AEW541 dose-dependently inhibited the proliferation of colorectal carcinoma cell lines and primary cell cultures by inducing apoptosis and cell cycle arrest. Apoptosis was characterized by caspase-3 activation and nuclear degradation. Cell cycle was arrested at the G1/S checkpoint. The NVP-AEW541-mediated cell cycle-related signaling involved the inactivation of Akt and extracellular signal-regulated kinase (ERK) 1/2, the upregulation of the cyclin-dependent kinase inhibitors p21(Waf1/CIP1) and p27(Kip1), and the downregulation of the cell cycle promoter cyclin D1. Moreover, BAX was upregulated during NVP-AEW541-induced apoptosis, whereas Bcl-2 was downregulated. Measurement of LDH release showed that the antineoplastic effect of NVP-AEW541 was not due to general cytotoxicity of the compound. However, augmented antineoplastic effects were observed in combination treatments of NVP-AEW541 with either 5-FU, or the EGFR-antibody cetuximab, or the HMG-CoA-reductase inhibitor fluvastatin.
conclusionIGF-1R-TK inhibition is a promising novel approach for either mono- or combination treatment strategies of colorectal carcinoma and even for CRC chemoprevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.